⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492274 | 1.00 | — | — | |
| SCHEMBL1688563 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL10321995 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL1932005 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3116731 | 0.97 | — | — | |
| SCHEMBL14551499 | 0.76 | — | — | |
| SCHEMBL6840071 | 0.74 | — | — | |
| SCHEMBL403601 | 0.73 | — | — | |
| SCHEMBL21479 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL16109776 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | claimed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | claimed |
| JP-2007510739-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1682551-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005047287-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | WO | claimed |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705292-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1680424-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | Neurogen Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005023806-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| CN-1161477-C | Enzyme-catalyzed racemic cleavage of primary a mines | BASF | 2004-08-11 | — | — | CN | disclosed |
| EP-1119634-B1 | ENZYME-CATALYZED RACEMIC CLEAVAGE OF PRIMARY AMINES | BASF AG (DE) | 2004-05-26 | — | — | EP | disclosed |
| US-6465223-B1 | Enzyme-catalyzed racemic cleavage of primary amines | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-15 | — | — | US | disclosed |
| CN-1313905-A | Enzymatic racemic resolution of primary amines | BASF AG (DE) | 2001-09-19 | — | — | CN | disclosed |
| US-6071492-A | Cardiac tropism radiopharmaceutical products incorporating a nitride complex of a transition metal and having a rapid myocardial clearance | CIS BIO INTERNATIONAL (FR) | 2000-06-06 | — | — | US | disclosed |